Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs

https://doi.org/10.1016/j.forsciint.2004.12.003Get rights and content

Abstract

While ethanol is primarily metabolized to acetaldehyde and acetic acid via alcohol dehydrogenase, a minor but increasingly important pathway in the field of forensic science involves the conjugation of glucuronic acid to form an ethyl glucuronide (EtG) metabolite. The kinetics of ethyl glucuronide formation were examined in human liver microsomes (HLM) and recombinant UDP-glucuronosyltransferases (UGTs). The metabolite exhibited a relatively slow rate of formation in a human liver microsome mix of 75.4 pmol/(min/mg). Further investigation identified multiple UGT isoforms to be responsible for catalyzing the addition of glucuronic acid to ethanol, with UGT1A1 and 2B7 being the two most prevalent isoforms. Co-incubation with bilirubin or 3′-azido-3′-deoxythymidine (UGT1A1 and 2B7 inhibitors, respectively) inhibited the greatest amount of ethyl glucuronide formation, though other UGT inhibitors also showed some effect. Enzyme kinetics were performed in human liver microsomes and recombinant UGT enzymes. The apparent Km (Kmapp) and Vmax values were determined to be 0.17 ± 0.08 mM and 75.98 ± 5.63 pmol/(min/mg) (human liver microsomes), 0.03 ± 0.01 mM and 25.22 ± 3.45 pmol/(min/mg) (UGT1A1), and 0.11 ± 0.04 mM and 52.03 ± 9.8 pmol/(min/mg) (UGT2B7). Thus, it appears that multiple UGTs are responsible for the formation of ethyl glucuronide and that any functional differences in the enzymology underlying ethyl glucuronide formation would most likely be masked by a combination of other enzymatic pathways.

Introduction

A significant amount of research has focused on finding a useful and reliable marker of alcohol consumption. Such a marker would potentially allow clinicians, researchers, and forensic experts to focus on groups with an increased risk of alcoholism, monitor current treatment programs more effectively, and determine the extent to which alcohol plays a role in the neurological impairment of drivers involved in accidents [1]. While hepatic clearance of ethanol is primarily catalyzed by alcohol dehydrogenase, the microsomal ethanol-oxidizing system and aldehyde dehydrogenase [2], [3], a minor, but forensically significant clearance pathway, involves ethanol conjugation with glucuronic acid [4], [5], [6], [7].

Formation of ethyl glucuronide (EtG) is characterized by the net addition of glucuronic acid to ethanol. This clearance pathway is catalyzed by the UDP-glucuronosyltransferase (UGT) superfamily of enzymes, which utilize UDP-glucuronic acid as a cofactor [8]. UGTs catalyze a very wide range of both xenobiotic and endogenous compounds, and as such, any noted polymorphisms in this family could potentially have toxicological, pharmacological, and forensic implications. UGT1A1, 1A6, 1A7, 2B4, 2B7, and 2B15 have all been shown to be polymorphic enzymes [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], though only the UGT1A1 polymorphism appears to translate into any functional significance [19], [20].

Approximately 0.02–0.06% of the total amount of ethanol consumed is eliminated as EtG [21], [22]. This minor pathway often results in urine EtG concentrations in the low ng/mL range [23]; however, the forensic importance of the pathway lies in the fact that clearance of EtG occurs at a much slower rate than that of ethanol [24], [25]. While serum and/or urine ethanol levels can normally only be detected for a few hours post-intake, urinary levels of EtG have been detected as long as 3–5 days following alcohol consumption [26], [27], [28]. Even though alcohol dehydrogenase, CYP2E1, and catalase mediated formation of acetaldehyde represent the major clearance pathways of ethanol, well-documented polymorphisms in the above-noted pathways coupled with rapid sequential metabolism to acetic acid would make analysis of this clearance mechanism much more complex [29]. Thus, forensic scientists have been using the advantageous properties of EtG in studying drunk driving cases, covert alcohol use among psychiatric inpatients, and multiple other situations in which alcohol consumption was thought to play a role [30], [31].

While the clearance of ethanol is a well-researched topic, the enzymology underlying the glucuronidation of ethanol has not received as much attention to date. Considering its use as a significant tool in forensic science, coupled with the polymorphic tendencies of the UGT family of enzymes, we felt it only prudent to explore the individual UGT isoforms responsible for catalyzing the formation of EtG. Metabolism by a single, polymorphic UGT could potentially lead to a skewed analysis of alcohol consumption. With this in mind, we have examined the formation of EtG in various in vitro systems. Using human liver microsomes (HLM) and recombinant UGTs, kinetic values were determined for the formation of EtG, and the effects of various inhibitors on the formation rate of the metabolite were studied. Finally, these data were scaled and compared to reported in vivo data for the clearance of ethanol in humans.

Section snippets

Materials and methods

Ethyl glucuronide was purchased from Medichem (Stuttgart, Germany). Methyl β-d-glucuronide and UDPGA were obtained from Sigma–Aldrich (St. Louis, MO). Ethanol (200 proof; ACS/USP grade) was purchased from Pharmco (Brookfield, CT). Human liver microsomes were obtained from a PGRD in-house supply and prepared in a method similar to that described in Kalvass et al. [32]. The human liver microsomes are a mixture of 60 individual livers and represent average activities of CYP1A2, CYP2C9, CYP2C19,

Results

Formation rates of EtG were determined in human liver microsomes and recombinant UGT enzymes. Kinetic parameters were examined in both systems as well. Finally, the effects of various UGT inhibitors on the formation rate of EtG were studied.

Initial experiments to determine the rate of formation of EtG in human liver microsomes were conducted at an ethanol concentration of 17 mM, a concentration approximately equivalent to a 0.1% blood alcohol content. The rate of formation was determined to be

Discussion

The forensics field has focused much effort on the ability to detect alcohol consumption. While standard methods still include the direct quantitation of ethanol in serum samples, newer methods have allowed for prolonged detection of ethanol intake. Monitoring such indicators as gamma glutamyltransferase, mean corpuscular volume, and carbohydrate deficient transferrin have all been used as markers of prolonged ethanol consumption [40]. More recently, analysis of fatty acid ethyl esters,

Acknowledgement

The authors would like to thank Dr. Cliff Fisher (Barker Institute, Groton, CT) for helpful discussions.

References (52)

  • H. Matsumoto et al.

    Pharmacokinetics of ethanol: a review of the methodology

    Addict. Biol.

    (2002)
  • I.A. Kamil et al.

    A new aspect of ethanol metabolism: isolation of ethyl-glucuronide

    Biochem. J.

    (1952)
  • T. Kozu

    Gas chromatographic analysis of ethyl-β-d-glucuronide in human urine

    Shinzu Igaku Zasshi

    (1973)
  • K. Besserer et al.

    Ein Beitrag zur renalen Ausscheidung von Äthylglucuronid nach oraler Alkoholaufnahme [a contribution on the renal excretion of ethyl glucuronide following oral ethanol intake]

    Zentralbl. Rechtsmed.

    (1983)
  • G.J. Dutton
  • P.J. Bosma et al.

    The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome

    N. Engl. J. Med.

    (1995)
  • E. Beutler et al.

    Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

    Proc. Natl. Acad. Sci. U.S.A.

    (1998)
  • B. Burchell et al.

    Molecular genetic basis of Gilbert syndrome

    J. Gastroenterol. Hepatol.

    (1999)
  • M. Ciotti et al.

    Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications

    Pharmacogenetics

    (1997)
  • J.W. Lampe et al.

    UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations

    Pharmacogenetics

    (1999)
  • C. Guillemette et al.

    Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene

    Pharmacogenetics

    (2000)
  • E. Levesque et al.

    Characterisation and substrate specificity of UGT2B4(E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene

    Pharmacogenetics

    (1999)
  • J.W. Lampe et al.

    Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)

    Cancer Epidemiol. (Biomarkers Prev.)

    (2000)
  • C.R. Bhasker et al.

    Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance

    Pharmacogenetics

    (2000)
  • E. Levesque et al.

    Isolation and characterisation of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene

    Pharmacogenetics

    (1997)
  • M.W.H. Coughtrie et al.

    The role of sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs) in human drug clearance and bioactivation

  • Cited by (117)

    • Non-oxidative ethanol metabolism in human hepatic cells in vitro: Involvement of uridine diphospho-glucuronosyltransferase 1A9 in ethylglucuronide production

      2020, Toxicology in Vitro
      Citation Excerpt :

      The overall SULT and UGT induction remained rather weak in our acute condition of ethanol treatment of HepaRG cells. Previous studies have reported that UGT1A1, UGT1A9 and UGT2B7 catalyzed the formation of EtG using recombinant UGTs (Foti and Fisher, 2005; Schwab and Skopp, 2014) while patients suffering from Gilbert's syndrome who have much lower expression in UGT1A1 show no differences in EtG formation following exposure to ethanol (Huppertz et al., 2015). We have recently demonstrated that CHZ [5-chloro-2(3H)-benzoxazolone], a centrally acting myorelaxant indicated for musculoskeletal pain (Chou et al., 2004), produced CHZ-O-Glc following the CYP2E1-mediated formation of OH-CHZ (Quesnot et al., 2018).

    • Sensitivity and specificity of a commercial urinary ethyl glucuronide (ETG) test in heavy drinkers

      2020, Addictive Behaviors Reports
      Citation Excerpt :

      The most frequently used measures include ethyl glucuronide (EtG), ethyl sulphate (EtS), and phosphatidylethanol (PEth). EtG is a phase 2 metabolite of alcohol that can be detected in urine, whole blood, serum, and hair (Foti & Fisher, 2005; Kissack, Bishop, & Roper, 2008; Wurst et al., 2015). EtG can be detected in urine for up to 80 h after ethanol consumption depending on the amount of alcohol consumed (Kissack et al., 2008; Wurst et al., 2015).

    • Alcohol biomarkers: Clinical issues and analytical methods

      2019, Critical Issues in Alcohol and Drugs of Abuse Testing
    • Nrf2 in alcoholic liver disease

      2018, Toxicology and Applied Pharmacology
      Citation Excerpt :

      As shown in Fig. 1, this reaction is an FAEE synthase-mediated esterification of lipids and ethanol (Doyle et al., 1996). Only a small proportion (0.6–1.5%) of ethanol may be transformed into EtG, in which ethanol is conjugated with UDP-glucuronic acid, catalyzed by the UDP-glucuronosyltransferase superfamily of enzymes (Foti and Fisher, 2005). EtS is produced when ethanol reacts with sulfate catalyzed by a superfamily of cytosolic sulfotransferases.

    View all citing articles on Scopus
    View full text